Bentazepam

Bentazepam
Clinical data
Trade namesTiadipona (ES)
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral (tablets)
ATC code
Legal status
Legal status
  • US: Unscheduled
Pharmacokinetic data
MetabolismHepatic
Elimination half-life2–4 hours
ExcretionRenal
Identifiers
  • 5-phenyl-3,4,6,7,8,9-hexahydro-[1]benzothiolo[2,3-e][1,4]diazepin-2-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.123.659 Edit this at Wikidata
Chemical and physical data
FormulaC17H16N2OS
Molar mass296.39 g·mol−1
3D model (JSmol)
  • O=C1CN=C(C2=CC=CC=C2)C3=C(N1)SC4=C3CCCC4
  • InChI=1S/C17H16N2OS/c20-14-10-18-16(11-6-2-1-3-7-11)15-12-8-4-5-9-13(12)21-17(15)19-14/h1-3,6-7H,4-5,8-10H2,(H,19,20) checkY
  • Key:AIZFEOPQVZBNGH-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Bentazepam[1] (also known as Thiadipone, Tiadipona) is a thienodiazepine which is a benzodiazepine analog.[2]

It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Peak plasma rates are achieved in around 2,5 hours after oral administration.[3] The elimination half-life is between approximately 2–4 hours.[2][4] Bentazepam is effective as an anxiolytic.

A severe benzodiazepine overdose with bentazepam may result in coma and respiratory failure.[5] Adverse effects include dry mouth, somnolence, asthenia, dyspepsia, constipation, nausea[6] and drug-induced lymphocytic colitis has been associated with bentazepam.[7][8] Severe liver damage and hepatitis has also been associated with bentazepam.[9][10][11] Whilst liver failure from bentazepam is considered to be rare, liver function monitoring has been recommended for all patients taking bentazepam.[12]

  1. ^ DE 2005276 
  2. ^ a b Gonzalez López F, Mariño EL, Dominguez-Gil A (September 1986). "Pharmacokinetics of tiadipone: a new anxiolytic". International Journal of Clinical Pharmacology, Therapy, and Toxicology. 24 (9): 482–4. PMID 2877954.
  3. ^ Mariño EL, Fernandez Lastra C, Gonzalez Lopez F, Dominguez-Gil A, Garcia Santalla JL, Vorca G, et al. (November 1987). "Parametrization by non-linear regression and bayesian estimation of bentazepam in a multiple dosage regimen in humans". International Journal of Clinical Pharmacology, Therapy, and Toxicology. 25 (11): 627–32. PMID 3429066.
  4. ^ Colino CI, Lastra CF, López FG, Ledesma A, Mariño EL (November 1991). "Open-loop feedback control of serum bentazepam concentrations and Bayesian estimation in multiple dosage regimens in patients". International Journal of Clinical Pharmacology, Therapy, and Toxicology. 29 (11): 457–62. PMID 1800395.
  5. ^ Rivas López FA, López Soriano F, Mendoza Cerezo A, Jiménez Ferré J, Azurmendi Rodríguez JI, de la Rubia Nieto MA (1989). "[Mixed benzodiazepine poisoning and reversal with flumazenil (Ro 15-1788)]". Revista Espanola de Anestesiologia y Reanimacion. 36 (1): 48–50. PMID 2565591.
  6. ^ Honorato J, Rubio A, Tristán C, Otero FJ, Garrido J (1990). "[A pharmacovigilance study with bentazepam in a sample of 1046 psychiatric outpatients]". Revista de Medicina de la Universidad de Navarra. 34 (2): 80–8. PMID 1983365.
  7. ^ Fernández-Bañares F, Salas A, Esteve M, Espinós J, Forné M, Viver JM (February 2003). "Collagenous and lymphocytic colitis. evaluation of clinical and histological features, response to treatment, and long-term follow-up". The American Journal of Gastroenterology. 98 (2): 340–7. doi:10.1111/j.1572-0241.2003.07225.x. PMID 12591052. S2CID 1983209.
  8. ^ de-la-Serna C, Gil-Grande LA, Sanromán AL, Gonzalez M, Ruiz-del-Arbol L, Garcia Plaza A (December 1997). "Bentazepam-induced hepatic bridging necrosis". Journal of Clinical Gastroenterology. 25 (4): 710–1. doi:10.1097/00004836-199712000-00042. PMID 9451703.
  9. ^ Andrade RJ, Lucena MI, Kaplowitz N, García-Muņoz B, Borraz Y, Pachkoria K, et al. (December 2006). "Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry". Hepatology. 44 (6): 1581–8. doi:10.1002/hep.21424. PMID 17133470. S2CID 9067701.
  10. ^ Tuca A (2003). "Utilidad clinica del acetato de megestrol para la ganancia de peso en los enfermos con neoplasia y caquexia". Medicina Clínica (in Spanish). 120 (17): 678. doi:10.1157/13047309. Archived from the original on 2018-09-16. Retrieved 2009-09-18.
  11. ^ Andrade RJ, Lucena MI, Alcantara R, Fraile JM (April 1994). "Bentazepam-associated chronic liver disease". Lancet. 343 (8901): 860. doi:10.1016/S0140-6736(94)92065-6. PMID 7908109. S2CID 33991843.
  12. ^ Andrade RJ, Lucena MI, Aguilar J, Lazo MD, Camargo R, Moreno P, et al. (July 2000). "Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity". Digestive Diseases and Sciences. 45 (7): 1400–4. doi:10.1023/A:1005520523502. PMID 10961721.